Human EpCAM _CD326 Protein Vector: HEK293
- Known as:
- Human EpCAM _CD326 Protein Vector: HEK293
- Catalog number:
- 10115-H01H
- Product Quantity:
- 100μg
- Category:
- -
- Supplier:
- Provo
- Gene target:
- Human EpCAM _CD326 Protein Vector: HEK293
Related genes to: Human EpCAM _CD326 Protein Vector: HEK293
- Gene:
- EPCAM NIH gene
- Name:
- epithelial cell adhesion molecule
- Previous symbol:
- M4S1, MIC18, TACSTD1
- Synonyms:
- Ly74, TROP1, GA733-2, EGP34, EGP40, EGP-2, KSA, CD326, Ep-CAM, HEA125, KS1/4, MK-1, MH99, MOC31, 323/A3, 17-1A, TACST-1, CO-17A, ESA
- Chromosome:
- 2p21
- Locus Type:
- gene with protein product
- Date approved:
- 1995-10-02
- Date modifiied:
- 2019-04-23
Related products to: Human EpCAM _CD326 Protein Vector: HEK293
Related articles to: Human EpCAM _CD326 Protein Vector: HEK293
- Breast cancer (BC) remains a predominant cause of mortality among women, with early diagnosis and ongoing monitoring being crucial for effective management. Integrating nuclear medicine with radiological modalities offers non-invasive anatomical and functional information, enabling precise target localization and quantification. This approach guided the selection of the most appropriate personalized treatment and predicted its efficacy, reducing the use of unnecessary drugs and lowering patient management costs. Since 2020, significant breakthroughs have been made in the development of radiopharmaceuticals, which are different in importantly targeting agents and radionuclides, with a focus on their efficacy in preclinical studies. This review accentuates the central role of radiopharmaceuticals in recent advancements for both imaging and therapeutic applications in BC. We discussed various receptor-targeted radiopharmaceutical therapy (RPT) agents currently utilized in clinical and preclinical settings with their chemical structures, along with the challenges faced in their implementation, including angiotensin II type 1 receptor (AT1 receptor), integrins αvβ3, chemokine receptor (CXCR4), and trophoblast cell-surface antigen-2 (TROP2), cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor, and epithelial cell adhesion molecule (EpCAM)-targeted, epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), fibroblast activation protein inhibitor (FAPI), and mucin 1 (MUC1). While numerous promising RPT agents were still in preclinical stages, this review underscored the potential of tailored radiopharmaceuticals to enhance BC diagnosis and treatment, providing novel avenues for personalized medicine. - Source: PubMed
Publication date: 2025/03/13
Rahmati HivaMousavi Seyed MehdiSouri ZobinFarzipour SoghraTavani Amin EbrahimiJalali-Zefrei Fatemeh - SYL3C is an optimized DNA aptamer with high selectivity and affinity for the epithelial cell adhesion molecule (EpCAM), an overexpressed tumor antigen in colorectal cancer (CRC). While its cellular affinity has been validated, in vivo studies are lacking. - Source: PubMed
Publication date: 2025/03/19
Huang ZhidieLi PinghuiLi YiwenDuan XiaoyanLi MengtingJiang DaweiLi Jianbo - Hypoparathyroidism (HPO) is characterized by deficient secretion of parathyroid hormone (PTH), leading to hypocalcemia and disrupted calcium homeostasis. Current treatments rely on calcium and vitamin D supplementation, which do not adequately mimic physiological PTH function. Cell-based therapies offer a potential solution, but optimal culture conditions to preserve the functional properties of primary parathyroid cells remain unclear. This study aims to develop primary rat parathyroid cell cultures that maintain hormone secretion and calcium-sensing abilities and to evaluate their therapeutic potential in a rat model of HPO. - Source: PubMed
Publication date: 2025/02/25
Ma KeYang ZeyuHuang YindeYin SupengSun YizengWang WeihuaYin TingjieZhu JunpingShi ChunmengZhang Fan - The isolation and detection of circulating tumor cells (CTCs) play a significant role in early cancer diagnosis and prognosis. Negative magnetophoresis sorting is a label-free method, providing easy access to enrich intact and viable CTCs, but it struggles to meet the demands of high-throughput separation and direct downstream analysis. In this work, a facile cascaded negative magnetophoresis microfluidic chip was fabricated and online coupled to inductively coupled plasma mass spectrometry (ICP-MS) for the rapid separation and detection of rare CTCs in blood samples. The chip consisted of two parts: a negative magnetophoresis sorting zone and a negative magnetophoresis phase-transfer zone. In the sorting zone, WBCs labeled with anti-CD45-magnetic beads (MBs) dispersed in biocompatible ferrofluid were removed by magnetic attractive force, while CTCs labeled with anti-EpCAM-Eu migrated into the phase-transfer zone by magnetic repulsive force; in the phase-transfer zone, due to the stable laminar flow formed by the magnetic fluid and PBS buffer, CTCs migrated into the PBS under both the magnetic repulsive force and inertial lift force and online introduced into ICP-MS for detection. This device can achieve CTC enrichment at a high throughput of 100 μL min and has the capability for direct downstream analysis and recultivation (cell viability of 99.27%). The method was applied for the detection of CTCs in real clinical blood samples from 10 patients diagnosed with various cancers, and the detection rate was 100%, providing a simple and efficient approach for clinical detection of rare CTCs. - Source: PubMed
Publication date: 2025/03/20
Fu XuelianChen BeibeiHe ManYuan GuolinHu Bin - Ovarian cancer (OvCa) is a prevalent gynecological malignancy with an increasing incidence and high mortality rate. Although the role of the herpesvirus entry mediator (HVEM), encoded by the TNFRSF14 gene, is currently considered pivotal in various types of cancer, the regulation of tumor cell-expressed HVEM in OvCa remains inadequately understood. - Source: PubMed
Lu YunZhang YijunLi WenxuanJiang HaonanWang JiapoGuo Xiaoqing